 Sage Therapeutics Inc NASDAQ: SAGE and Biogen Inc NASDAQ: BIIB have scored their first but narrow win after signing their 3.1 billion deal last year in November. SAGE-324, the second major molecule in the pact, cleared a Phase 2 trial for essential tremor ET, a progressive disorder that causes involuntary muscle movement. 